Seattle Genetics (NASDAQ:SGEN) and collaboration partner Astellas Pharma (OTCPK:ALPMF) announce the filing of a U.S. marketing application seeking approval for antibody-drug conjugate enfortumab vedotin for the treatment of patients with locally advanced/metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received platinum-based chemo in the neoadjuvant/adjuvant, locally advanced or metastatic setting, a Breakthrough Therapy-tagged indication.
The companies are co-developing enfortumab vedotin under an original 2007 agreement, equally sharing global costs and profits.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.